Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0174-1213 in Male Participants With Overweight or Obesity
NCT06719011Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0174-1213 in obesity (6 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment-Emergent Adverse Events at Day 67. Started Dec 2024; status: completed.
02
Drugs
NNC0174-1213
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06719011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719011.